{"id":7486,"date":"2020-06-11T14:25:57","date_gmt":"2020-06-11T21:25:57","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=7486"},"modified":"2021-03-25T14:26:37","modified_gmt":"2021-03-25T21:26:37","slug":"effects-of-tocilizumab-on-mortality-in-hospitalized-patients-with-covid-19-a-multicenter-cohort-study","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/11\/effects-of-tocilizumab-on-mortality-in-hospitalized-patients-with-covid-19-a-multicenter-cohort-study\/","title":{"rendered":"Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19 A Multicenter Cohort Study"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"2019\" data-aria-level=\"1\"><i><span data-contrast=\"none\">[pre-print, not peer reviewed]<\/span><\/i><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">Martinez-Sanz et al.<\/span><span data-contrast=\"auto\">\u00a0conducted a cohort study of 1,229 patients with COVID-19 in Spain to determine the relationship between tocilizumab use and ICU admission or death. Tocilizumab was associated with decreased risk of death (<\/span><span data-contrast=\"auto\">aHR<\/span><span data-contrast=\"auto\">=<\/span><span data-contrast=\"auto\">0.34, 95%CI 0.16-0.72) and ICU admission or death (0.38, 0.19-0.81; p=0.011) among patients with\u00a0<\/span><span data-contrast=\"auto\">high C<\/span><span data-contrast=\"auto\">&#8211;<\/span><span data-contrast=\"auto\">reactive protein (CRP) levels (<\/span><span data-contrast=\"auto\">&gt;150 mg\/L<\/span><span data-contrast=\"auto\">)<\/span><span data-contrast=\"auto\">. There was no association with low rates of death or ICU admission\u00a0<\/span><span data-contrast=\"auto\">among those with CRP\u00a0<\/span><span data-contrast=\"auto\">\u00a3<\/span><span data-contrast=\"auto\">150 mg\/L<\/span><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Martinez-Sanz et al. (June 9, 2020). Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19 A Multicenter Cohort Study. Pre-print downloaded June 11 from\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2020.06.08.20125245\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1101\/2020.06.08.20125245<\/span><\/a><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[pre-print, not peer reviewed]\u00a0Martinez-Sanz et al.\u00a0conducted a cohort study of 1,229 patients with COVID-19 in Spain to determine the relationship between tocilizumab use and ICU admission or death. Tocilizumab was associated with decreased risk of death (aHR=0.34, 95%CI 0.16-0.72) and ICU admission or death (0.38, 0.19-0.81; p=0.011) among patients with\u00a0high C&#8211;reactive protein (CRP) levels (&gt;150&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/11\/effects-of-tocilizumab-on-mortality-in-hospitalized-patients-with-covid-19-a-multicenter-cohort-study\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[19],"class_list":["post-7486","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=7486"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7486\/revisions"}],"predecessor-version":[{"id":7487,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7486\/revisions\/7487"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=7486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=7486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=7486"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=7486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}